Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 1 to 50 of 295

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
10395 - Aprocitentan for treating resistant hypertension TS ID 10395	Technology appraisal guidance
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years TSID 12049	Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095	Technology appraisal guidance
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]	Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]	Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]	Technology appraisal guidance
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232	Technology appraisal guidance
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]	Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture [ID6276]	Technology appraisal guidance
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]	Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830	Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036	Technology appraisal guidance
Ambulatory pulmonary artery pressure monitoring devices	Diagnostics guidance
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]	Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471	Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia	Medical technologies guidance
Artificial intelligence technologies for mammography: early value assessment	Health technology evaluation
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance
Balloon cryoablation for Barrett's oesophagus	Interventional procedures guidance
Baloxavir marboxil for Influenza	Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476	Technology appraisal guidance
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer ID6481	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769	Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]	Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550	Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054	Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334	Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592	Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine ID 6450	Technology appraisal guidance
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over ID 6448	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID 6437	Technology appraisal guidance
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486	Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]	Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]	Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]	Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666	Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888	Technology appraisal guidance
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466	Technology appraisal guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214	Technology appraisal guidance

Results per page

10
25
50
All